Abstract
Chemotherapy has been an important part of cancer treatment for many years. However, its efficacy is often limited because conventional chemotherapy can cause serious side effects and lead to differences in treatment response between patients. At this point, personalized medicine offers a new approach to eliminating these problems in cancer treatment. Personalized medicine proposes organizing treatment according to the genetic and molecular characteristics of both the tumor and the patient with tailored treatment regimens. Through molecular profiling of the patient and the tumor, oncologists can have a preliminary idea about the most effective drug, allowing them to adjust the treatment specifically for the individual and minimize the harmful effects on healthy tissues. Advances in genomics and precision oncology, and also new platforms such as organoids and organ-on-chips, have made it possible to select drugs, based on tumor-specific biomarkers, genomic alterations, and pharmacogenomic variants.
However, there are still some challenges in applying personalized chemotherapy. The main reasons are concerns about the reliability of biomarkers, integration of genomic data into clinical practice, cost-effectiveness, and ethical issues related to genetic privacy. This review summarizes the basic concepts of tumor biology and chemotherapy and discusses how personalized medicine and precision oncology are changing cancer treatment.
References
- Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, et al. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103(2): 210–216.
- Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, et al. (2022). Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 10(4): 1367–1401.
- Bartolomucci A, Nobrega M, Ferrier T, et al. (2025). Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol 9: 84.
- Batlle E, Clevers H (2017). Cancer stem cells revisited. Nat Med 23(10): 1124–1134.
- Castillo DR, Guo M, Shah P, et al. (2025). CLDN18.2 and PD-L1 profiling in gastric cancer. Transl Oncol 28: 101065.
- Chitrangi S, Vaity P, Jamdar A, Bhatt S (2023). Patient-derived organoids for precision oncology: A platform to facilitate clinical decision making. BMC Cancer 23: 689.
- de With M, van Doorn L, Kloet E, van Veggel A, Matic M, et al. (2023). Irinotecan-induced toxicity: A pharmacogenetic study beyond UGT1A1. Clin Pharmacokinet 62: 1589–1597.
- Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, et al. (2022). Multidrug resistance in cancer: Understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol 12: 891652.
- Fan S, Qingyu M, Zhao Z, Niu W (2025). Long-term response in rare MSI-H CRC with BRAF mutation. Front Immunol 16: 1698410.
- Ghoreyshi N, Heidari R, Farhadi A, Chamanara M, Farahani N, et al. (2025). Next-generation sequencing in cancer diagnosis and treatment: Clinical applications and future directions. Discov Oncol 16(1): 578.
- Grodzka A, Knopik-Skrocka A, Kowalska K, Kurzawa P, Krzyżaniak M, et al. (2023). Molecular alterations of driver genes in non-small cell lung cancer: From diagnostics to targeted therapy. EXCLI J 22: 415–432.
- Hanahan D (2022). Hallmarks of cancer: New dimensions. Cancer Discov 12(1): 31–46.
- Jin H, Yang Y, Yan C, Liu M, Heet X, et al. (2025). Tumor immunophenotyping in HER2+ breast cancer. Mol Cancer 24: 483.
- Kaufman NEM, Dhingra S, Jois SD, Vicente MGH (2021). Molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). Molecules 26(4): 1076.
- Kim C, Gao R, Sei E, Brandt R, Hartman J, et al. (2018). Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell 173(4): 879–893.e13.
- Kim J, Koo BK, Knoblich JA (2020). Human organoids: Model systems for human biology and medicine. Nat Rev Mol Cell Biol 21: 571–584.
- Klug M, Kirshenboim Z, Truong MT, Sorin V, Keren Gilat E, et al. (2025). The ninth edition TNM staging system for thymic epithelial tumors: A comprehensive review. Radiol Cardiothorac Imaging 7(5).
- Li R, Liu X, Huang X, Zhang D, Chen Z, et al. (2024). Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis. Gut 73(3): 470–484.
- Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL (2020). Molecular profiling for precision cancer therapies. Genome Med 12(1): 8.
- Martin de la Fuente L, Westbom-Fremer S, Arildsen NS, Hartman L, Malander S, et al. (2020). PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. Virchows Arch 477(1): 83–91.
- Mohan N, Luo X, Shen Y, Olson Z, Agrawal A, et al. (2021). A novel bispecific antibody targeting EGFR and VEGFR2 is effective against triple negative breast cancer via multiple mechanisms of action. Cancers 13(5): 1027.
- Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, et al. (2018). Maintenance olaparib in newly diagnosed advanced ovarian cancer. N Engl J Med 379(26): 2495–2505.
- Pernik MN, Bird CE, Traylor JI, Shi DD, Richardson TE, et al. (2021). Patient-derived cancer organoids for precision oncology treatment. J Pers Med 11(5): 423.
- Ren X, Huang M, Weng W, Xie Y, Wu Y, et al. (2023). Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application. Cell Rep Med 4(11): 101277.
- Qiao D, Wang RC, Wang Z (2025). Precision oncology: Current landscape, emerging trends, challenges, and future perspectives. Cells 14(22): 1804.
- Relling MV, Evans WE (2015). Pharmacogenomics in the clinic. Nature 526(7573): 343–350.
- Tilsed CM, Fisher SA, Nowak AK, Lake RA, Lesterhuis WJ (2022). Cancer chemotherapy: Insights into cellular and tumor microenvironmental mechanisms. Front Oncol 12: 960317.
- Trendowski MR, El Charif O, Dinh PC, Wheeler HE, Ardeshir-Rouhani-Fard S, et al. (2019). Genetic and modifiable risk factors contributing to cisplatin-induced toxicities. Clin Cancer Res 25(4): 1147–1155.
- Wang W, Gao M, Gao Y, Zheng H, Song N, et al. (2025). Integrating homologous recombination deficiency subtyping with TCGA molecular classification for enhanced prognostic stratification and personalised therapy in endometrial cancer. Br J Cancer.
- Yang Z, Carrio-Cordo P, Baudis M (2024). Copy number variation heterogeneity reveals biological inconsistency in hierarchical cancer classifications. Mol Cytogenet 17: 26.
- Yi K, Park SH, Kim DU, Jeon DY, Lee HJ, et al. (2023). Patient-derived organoid model for predicting the chemoresponse in patients with colorectal cancer. In Vivo 37(4): 1751–1759.
- Zazuli Z, Vijverberg S, Slob E, Liu G, Carleton B, et al. (2018). Genetic variations and cisplatin nephrotoxicity: A systematic review. Front Pharmacol 9: 1111.
- Zhao L, Song L, Wang H, Tian W, Xi J, et al. (2025). Post-translational modification gene signature for treatment response in breast cancer. Sci Rep 15: 23772.
Details
| Primary Language | English |
|---|---|
| Subjects | Pharmaceutical Sciences, Clinical Pharmacology and Therapeutics, Clinical Sciences (Other) |
| Journal Section | Review Article |
| Authors | |
| Submission Date | December 5, 2025 |
| Acceptance Date | December 19, 2025 |
| Early Pub Date | February 11, 2026 |
| Publication Date | December 26, 2025 |
| DOI | https://doi.org/10.54994/emujpharmsci.1836760 |
| IZ | https://izlik.org/JA87WH63KU |
| Published in Issue | Year 2025 Volume: 8 Issue: 3 |
Cite
Aim & Scope
EMU Journal of Pharmaceutical Sciences (EMUJPharmSci), which is an open access peer-reviewed journal, publishes original research, short reports and review articles. The contributions to the journal must be written in English. The journal has been published regularly three times a year since 2018.
The journal covers the research on all aspects of Pharmacy presented as original articles, short reports and reviews. In our journal, publications are the recent studies on the basis of Pharmaceutical Sciences including, Pharmaceutical Toxicology, Pharmaceutical Chemistry, Pharmacognosy, Pharmaceutical Botany, Pharmaceutical Technology, Pharmaceutical Biotechnology, Pharmaceutical Microbiology, Pharmacology and also other topics related with the pharmaceutical area.
Author Guidelines
- Contributions to EMU Journal of Pharmaceutical Sciences must be in English.
- All manuscripts are subject to editorial review.
- The manuscripts should not be previously published or accepted for publication and should not be submitted or under simultaneous consideration for publication elsewhere.
- The manuscripts are published in the order of final acceptance after review and revision.
- If the manuscript is returned to authors for revision and the revised manuscript is not received by the editor within 2 months it will be treated as a new article.
- If the manuscript is accepted and the proof is returned to the authors, corrected proofs should be sent to the editor within 5 days.
- The original manuscript must be arranged as follows: Title page (including the title, authors and correspondence address), abstract, key words, introduction, materials and methods, results and discussion, acknowledgements and references.
- The reviews must be arranged as follows: Title page (including the title, authors and correspondence address), abstract, introduction, discussion, acknowledgements and references.
e) All authors’ ORCID ID number (Font: Times New Roman Font Size: 11).
- Please ensure that every reference cited in the text is also present in the reference list (and vice versa).
- Unpublished results and personal communications are not recommended in the reference list.
- References in the text should be cited as: the author(s) surname and the publication date.
- The list of references should be single-spaced.
- List the references in alphabetical order under section of “references”.
- For references up to 5 authors, write the names of all authors.
- For references more than 5 authors, write the names of the first 5 and add et. al.
- The name of journal should be italicizes and abbreviated according to the style used in the National Library of Medicine’s Journals in NCBI Databases.
- Volume numbers should be indicated in bold letters.
- Use figures and tables when information cannot easily be stated or summarized in the manuscript itself.
- All the figures and tables must be referred to in the main body of the text.
- Tables and Figures should be numbered consequently in the order of appearance within the text, referred as “Table 1” and “Figure 1”.
- Descriptive titles should be given at the top of the tables and at the bottom of the figures.
- Figures should be prepared with the highest resolution and should be provided as a separate page following references.
- Full E-mail address, full postal address, telephone and fax number of the corresponding author.
- All necessary files have been uploaded.
- References are in the correct format for this journal.
- All references mentioned in the Reference list are cited in the text.
- All figure captions.
- All tables (including title, description, footnotes).
- For any further information please e-mail:
Ethical Principles and Publication Policy
ETHICAL RULES
EMU Journal of Pharmaceutical Sciences adopts the guidelines and policies published by the Committee on Publication Ethics (COPE) regarding academic and ethical standards, as well as the ethical rules stipulated in the Directive on Scientific Research and Publication Ethics of Higher Education Institutions issued by the Council of Higher Education.
ETHICAL RULES REGARDING RESEARCH
All research to be published in the journal must be conducted in accordance with scientific ethical principles and TR Dizin criteria.
• https://trdizin.gov.tr/wp-content/uploads/2022/04/TRDizin_etik_ilkeleri_akis_semasi.pdf
Declaration of Ethics Committee Approval and Legal Permissions
In accordance with TR Dizin criteria, it must be clearly stated whether ethics committee approval and/or legal or special permission is required for articles to be published in the journal. For studies requiring ethics committee approval or permission, the name of the institution granting approval, the date of approval, and the decision or reference number must be explicitly stated.
Statement of Ethical Information Within the Article
For studies involving human participants, it must be clearly stated in the “Methods” section of the article that informed consent was obtained from participants and that ethics committee approval was received from the relevant institution.
GENERAL RULES ON ETHICS AND PUBLICATION
Manuscript Review Stages
• Editors conduct a preliminary evaluation of submitted manuscripts as soon as possible.
• Manuscripts are first reviewed by editors for compatibility with the journal’s scope and objectives.
• Plagiarism detection software (iThenticate) is used for all submissions. Manuscripts with a similarity rate of 20% or higher, excluding references and quotations, are rejected directly during preliminary reviews. Even if the overall similarity rate is below 20%, the similarity from a single source must not exceed 2%. All plagiarism reports are carefully reviewed by the editor.
• Manuscripts not deemed suitable for the evaluation process are rejected during preliminary review with a justified explanation provided to the author. Reasons may include repetition of similar topics in recent issues, mismatch with the journal’s scope, recent publication by the same author, or plagiarism exceeding the allowed limit.
• If correctable deficiencies exist (e.g., excessive word count, missing keywords or abstract, incomplete information), the manuscript is returned to the author for revision. Authors are expected to inform the editor of the timeline for resubmission. Manuscripts without feedback within one month may be rejected.
• Manuscripts that pass preliminary reviews are sent to peer reviewers.
• Editors may decide to send submissions such as translations or book reviews (“notes”) for peer review if deemed necessary; however, this does not grant them the status of peer-reviewed articles.
Editors are responsible for maintaining the journal’s academic quality, scientific reliability, and publication ethics. Their responsibilities include:
1. Academic Priority and Scope Compliance: Editors prioritize academic criteria and scientific integrity, evaluating manuscripts that provide original and qualified contributions aligned with the journal’s aims.
2. Decision Authority and Responsibility: Final decisions regarding acceptance, rejection, or revision rest with the editors. Editors must avoid conflicts of interest and withdraw from the process when necessary.
3. Efficient Management of the Publication Process: Editors ensure that review, editorial, and publication stages proceed smoothly and within planned timelines.
4. Impartiality and Non-Discrimination: Manuscripts are evaluated solely on scientific merit, without regard to authors’ gender, race, ethnicity, religion, nationality, or political views.
5. Confidentiality: Editors ensure confidentiality throughout the peer review process and do not disclose manuscript-related information to third parties.
6. Prevention of Plagiarism and Ethical Violations: Editors ensure plagiarism screening and investigate suspected ethical violations thoroughly.
7. Integrity of Editorial Duties: Editorial positions are assigned only to individuals who actively contribute to the journal. All members are informed of confidentiality obligations.
ETHICAL RULES AND RESPONSIBILITIES OF AUTHORS
Authors agree to the following ethical principles and responsibilities:
1. Compliance with Publication Policy and Author Guidelines
2. Prohibition of Simultaneous Submission
3. Originality and Plagiarism Prohibition
4. Authorship Order and Contribution Responsibility
5. Scientific Integrity and Data Ethics
6. Permissions and Ethical Approvals
7. Declaration of Thesis-Based or Conference-Presented Works
8. Conflict of Interest Disclosure
9. Publication Process and Copyright Transfer
10. Data Sharing Obligation
11. Citation and Reference Use
12. Funding and Support Disclosure
13. Correction and Cooperation Obligation
14. Submission Limitation: Authors whose articles are published may submit a new manuscript only after two subsequent issues (one year).
ETHICAL RESPONSIBILITIES OF REVIEWERS
Reviewers accept the following ethical responsibilities:
1. Impartiality and Equality
2. Constructive and Respectful Evaluation
3. Expertise, Confidentiality, and Timely Review
4. Content-Fo
Editors are responsible for maintaining the journal’s academic quality, scientific reliability, and publication ethics. Their responsibilities include:
1. Academic Priority and Scope Compliance: Editors prioritize academic criteria and scientific integrity, evaluating manuscripts that provide original and qualified contributions aligned with the journal’s aims.
2. Decision Authority and Responsibility: Final decisions regarding acceptance, rejection, or revision rest with the editors. Editors must avoid conflicts of interest and withdraw from the process when necessary.
3. Efficient Management of the Publication Process: Editors ensure that review, editorial, and publication stages proceed smoothly and within planned timelines.
4. Impartiality and Non-Discrimination: Manuscripts are evaluated solely on scientific merit, without regard to authors’ gender, race, ethnicity, religion, nationality, or political views.
5. Confidentiality: Editors ensure confidentiality throughout the peer review process and do not disclose manuscript-related information to third parties.
6. Prevention of Plagiarism and Ethical Violations: Editors ensure plagiarism screening and investigate suspected ethical violations thoroughly.
7. Integrity of Editorial Duties: Editorial positions are assigned only to individuals who actively contribute to the journal. All members are informed of confidentiality obligations.
ETHICAL RULES AND RESPONSIBILITIES OF AUTHORS
Authors agree to the following ethical principles and responsibilities:
1. Compliance with Publication Policy and Author Guidelines
2. Prohibition of Simultaneous Submission
3. Originality and Plagiarism Prohibition
4. Authorship Order and Contribution Responsibility
5. Scientific Integrity and Data Ethics
6. Permissions and Ethical Approvals
7. Declaration of Thesis-Based or Conference-Presented Works
8. Conflict of Interest Disclosure
9. Publication Process and Copyright Transfer
10. Data Sharing Obligation
11. Citation and Reference Use
12. Funding and Support Disclosure
13. Correction and Cooperation Obligation
14. Submission Limitation: Authors whose articles are published may submit a new manuscript only after two subsequent issues (one year).
ETHICAL RESPONSIBILITIES OF REVIEWERS
Reviewers accept the following ethical responsibilities:
1. Impartiality and Equality
2. Constructive and Respectful Evaluation
3. Expertise, Confidentiality, and Timely Review
4. Content-Fo
• Submitted manuscripts undergo preliminary review by the editor. If deficiencies are identified or the manuscript is unsuitable, the author is informed.
• For manuscripts passing preliminary review, at least two expert reviewers are invited. As a principle, each manuscript undergoes evaluation by three reviewers. Authors should consider this process and potential time extensions when submitting manuscripts. A minimum of two positive reviewer reports is required for publication.
• Editors carefully evaluate negative reviewer reports and consider arguments against publication. If significant scientific deficiencies are identified, editors may decide to reject the manuscript and inform the author with justification.
• Reviewers who do not respond within 10 days receive reminders. If necessary, new reviewers are assigned. Invitations are canceled for reviewers who fail to respond or decline, and replacements are promptly appointed.
ETHICAL RESPONSIBILITIES OF EDITORS
Editors are responsible for maintaining the journal’s academic quality, scientific reliability, and publication ethics. Their responsibilities include:
1. Academic Priority and Scope Compliance: Editors prioritize academic criteria and scientific integrity, evaluating manuscripts that provide original and qualified contributions aligned with the journal’s aims.
2. Decision Authority and Responsibility: Final decisions regarding acceptance, rejection, or revision rest with the editors. Editors must avoid conflicts of interest and withdraw from the process when necessary.
3. Efficient Management of the Publication Process: Editors ensure that review, editorial, and publication stages proceed smoothly and within planned timelines.
4. Impartiality and Non-Discrimination: Manuscripts are evaluated solely on scientific merit, without regard to authors’ gender, race, ethnicity, religion, nationality, or political views.
5. Confidentiality: Editors ensure confidentiality throughout the peer review process and do not disclose manuscript-related information to third parties.
6. Prevention of Plagiarism and Ethical Violations: Editors ensure plagiarism screening and investigate suspected ethical violations thoroughly.
7. Integrity of Editorial Duties: Editorial positions are assigned only to individuals who actively contribute to the journal. All members are informed of confidentiality obligations.
ETHICAL RULES AND RESPONSIBILITIES OF AUTHORS
Authors agree to the following ethical principles and responsibilities:
1. Compliance with Publication Policy and Author Guidelines
2. Prohibition of Simultaneous Submission
3. Originality and Plagiarism Prohibition
4. Authorship Order and Contribution Responsibility
5. Scientific Integrity and Data Ethics
6. Permissions and Ethical Approvals
7. Declaration of Thesis-Based or Conference-Presented Works
8. Conflict of Interest Disclosure
9. Publication Process and Copyright Transfer
10. Data Sharing Obligation
11. Citation and Reference Use
12. Funding and Support Disclosure
13. Correction and Cooperation Obligation
14. Submission Limitation: Authors whose articles are published may submit a new manuscript only after two subsequent issues (one year).
ETHICAL RESPONSIBILITIES OF REVIEWERS
Reviewers accept the following ethical responsibilities:
1. Impartiality and Equality
2. Constructive and Respectful Evaluation
3. Expertise, Confidentiality, and Timely Review
4. Content-Focused Evaluation
5. Reasoned and Clear Reporting
6. Conflict of Interest Disclosure
7. Publication Ethics and Similarity Reporting
8. Confidentiality Obligation: Manuscripts must not be shared or uploaded to AI tools or plagiarism software.
9. Prohibition of Misuse of Information
10. Reporting Ethical Violations
11. Acceptance of Editorial Authority
12. Responsibility for Academic Quality
OPEN ACCESS POLICY
EMU Journal of Pharmaceutical Sciences follows an open access policy. Articles may be shared provided that proper citation is given.
PRIVACY STATEMENT
Names and email addresses submitted to the journal or listed on the website will be used solely for stated purposes and will not be shared or used for any other purpose.
Price Policy
All expenses of the journal are covered by the Eastern Mediterranean University. Processing and publication are free of charge with the journal. There is no article processing charges or submission fees for any submitted or accepted articles.
Journal Boards
Editorial Board
Doğu Akdeniz Üniversitesi Eczacılık Fakültesi Dekanı Prof. Dr. Hayrettin Ozan Gülcan 1999 yılında Hacetepe Üniversitesi Eczacılık Fakültesini ve 2001 yılında Gazi Üniversitesi Eczacılık Fakültesi Farmasötik Kimya Yüksek Lisans programını başarı ile tamamladıktan sonra 2004 yılında Amerika Birleşik Devletleri Iowa Üniversitesi Eczacılık Fakültesi Medicinal ve Doğal ürünler bölümü Doktora programına kaydolmuştur. 2008 yılında bu programdan mezun olup bilim doktoru ünvanını kazandıktan sonra Nobel İlaç Arge merkezinde Arge bölüm yöneticisi olarak çalışmaya başlamıştır. 2013 yılına kadar ilaç sanayinde ilaç ham maddesi sentezi ve orjinal ilaç tasarım ve aktivite tayin direktörlüğü görevlerinde bulunmuştur. 2013 yılında Doğu Akdeniz Üniversitesi’nde çalışmaya başlayan Dr. Gülcan 2017 yılında Farmasötik Kimya alanında Doçent ve 2022 yılında da Prof. ünvanını almıştır. Halen Doğu Akdeniz Üniversitesi Eczacılık Fakültesi Farmasötik Kimya öğretim üyeliği ile Fakülte dekanlığı görevlerini sürdürmektedir.
Kariyeri boyunca 60’ın üzerinde uluslararası orjinal araştırma makalesi hazırlamış, çok sayıda uluslararası kitap bölümü yazarlığı yapmıştır. 10’nun üzerinde Doktora öğrencisine tez danışmanlığı yapmış ve ulusal ve uluslararası pek çok buluşa imza atarak bu buluşların patentlerini almıştır. Çok sayıda bilimsel ödül sahibi olan Prof. Gülcan, mesleki ve bilimsel pek çok derneğin üyeliğini yapmaktadır.
Kariyerinin son 15 yılını Alzheimer Hastalığı başta olmak üzere nörodejeneratif hastalıklarının tedavisi üzerine bilimsel çalışmalar yaparak geçirmiştir. 2022 Yulından itibaren Yeditepe Üniversitesi Eczacılık Fakültesi Farmasötik Kimya Doktora programında da görev almaktadır. Aynı zamanda Khazar Üniveritesi Engineered Biomaterial Research Center üyesidir.
Advisory/Scientific Board
Tansel Çomoğlu, 1991 yılında Ankara Üniversitesi Eczacılık Fakültesi'nden mezun olmuştur. Aynı üniversitede Farmasötik Teknoloji alanında yüksek lisansını tamamladıktan sonra, 2002 yılında doktora derecesini almıştır.
2005 yılında TÜBİTAK tarafından verilen post-doktoral araştırma bursu ile Norveç'teki Tromso Üniversitesi Farmasötik ve Biyofarmasötik Bölümü'nde çalışmalarına devam etmiştir. 2010 yılında yardımcı doçent, 2011 yılında doçent unvanını almış olan Dr. Çomoğlu, 2012 yılında YÖK bursu ile ABD'nin Chicago kentindeki Illinois Üniversitesi Eczacılık Fakültesi Biyomühendislik ve Biyofarmasötik Bilimler Bölümü'nde çalışma fırsatı bulmuştur. 2017 yılında ise Ankara Üniversitesi Eczacılık Fakültesi Farmasötik Teknoloji Anabilim Dalı'na profesör olarak atanmıştır.
Dr. Çomoğlu, 2012 yılından itibaren çeşitli SCI dergilerinin hakem kurullarında yer almakta olup, 60’tan fazla bilimsel makale ve 6 uluslararası kitap bölümü yazmıştır. Araştırma ilgi alanları arasında beyin hedefli nanopartikül ilaç taşıyıcı sistemleri ve ağızda dağılan tabletler yer almaktadır.
Dr. Çomoğlu, akademik kariyerinde birçok ödüle layık görülmüştür. 2008 yılında "Diclofenac Potassium fast dispersing tablets’ın formülasyonu ve in-vitro değerlendirilmesi ile migren hastalarında klinik uygulamaları" konulu çalışmasıyla Novartis Proje Ödülü'nü kazanmıştır. 2021 yılında YÖK En İyi Doktora Tezi Ödülü’nü almış, 2022 yılında ise Dr. Özyılmaz ile birlikte Endüstri Odaklı Ar-Ge ve İnovasyon Yarışması Ödülü'nü kazanmıştır. Ayrıca, 2023 yılında Kariyer Geliştirme Odaklı AR-GE Projeleri Yarışması'nda 2.lik ödülünü ve 2024 yılında Başakşehir 11. İnovasyon Projeleri Yarışması'nda 3.lük ödülünü kazanarak başarılarını pekiştirmiştir.
